Ring BZ, et al. - Authors conducted an independent evaluation of the relationship of transducin-like enhancer of split 3 (TLE3) expression with response to taxane-based chemotherapy in nonserous ovarian cancer, to validate its role as a potential therapeutic response marker for taxane-based chemotherapy. As per results, in patients with nonserous ovarian cancer, the relation between high TLE3 expression and a favourable response to taxane-containing chemotherapy regimens was validated. In tumours with clear cell histology, strongest association between TLE3 expression and outcome was seen.